ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Holding(s) in Company
Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation proton therapy system for cancer treatment, has been informed that Odey Asset Management LLP has a total beneficial interest in20,281,159ordinary shares of 25p each in the Company, representing 4.3% of the Company's issued share capital.
Advanced Oncotherapy plc |
|
Dr. Michael Sinclair, Executive Chairman |
Tel: +44 (0) 20 3617 8728 |
|
Nicolas Serandour, CEO |
|
Allenby Capital Limited (Nomad and Joint Broker) |
|
|
Nick Athanas / Liz Kirchner (Corporate Finance) Amrit Nahal / Matt Butlin (Sales and Corporate Broking) |
Tel: +44 (0) 20 3328 5656 |
SI Capital Ltd (Joint Broker) |
|
Nick Emerson |
Tel: +44 (0) 1483 413 500 |
|
Jon Levinson |
Tel: +44 (0) 20 3871 4066 |
FTI Consulting (Financial PR & IR) |
|
Simon Conway / Rob Winder |
Tel: +44 (0) 20 3727 1000 |
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. ENDHOLUBAARUOUVUAR
==